Product Description
Mechanisms of Action: ADRB2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bangladesh | Brazil | Colombia | Ecuador | India | Italy | Korea | Pakistan | Philippines | Portugal | South Africa | Turkey | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Teikoku Pharma USA
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Chronic Obstructive Pulmonary Disease
Phase 2: Airway Obstruction|Asthma|Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20242657 | N/A |
Completed |
Emphysema|Bronchitis, Chronic|Asthma|Dyspnea |
2024-06-22 |
|
NCT04057469 | N/A |
Completed |
Anesthesia Related|Tonsillitis |
2021-09-30 |
|
2020-003796-17 | P2 |
Unknown status |
Parkinson's Disease |
2021-02-21 |
|
CTR20202310 | N/A |
Completed |
Asthma|Dyspnea|Emphysema|Bronchitis, Chronic |
2020-12-21 |